Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Abstract Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical coherence tomography (OCT) to predict...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-11-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-023-00850-6 |
| _version_ | 1797355937233633280 |
|---|---|
| author | Chu-Hsuan Huang Tso-Ting Lai Chang-Hao Yang Yi-Ting Hsieh |
| author_facet | Chu-Hsuan Huang Tso-Ting Lai Chang-Hao Yang Yi-Ting Hsieh |
| author_sort | Chu-Hsuan Huang |
| collection | DOAJ |
| description | Abstract Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical coherence tomography (OCT) to predict treatment outcomes. Methods Patients diagnosed with nAMD or PCV who received an intravitreal injection of aflibercept following the TnE regimen for ≥ 2 years were retrospectively reviewed. Data on best-corrected visual acuity (BCVA), number of injections, treatment interval, and OCT biomarkers, including central macular thickness, presence of subretinal fluid (SRF), and serous pigmented epithelial detachment, were collected at baseline and at 3, 6, 12, 18, and 24 months after the first injection. Results A total of 43 patients were enrolled in this study, 24 of whom were diagnosed with nAMD and 19 with PCV. The BCVA in logMAR (mean ± standard deviation) improved from 0.75 ± 0.41 (baseline) to 0.60 ± 0.41 (P = 0.002) at 3 months after treatment initiation, and further improved to 0.66 ± 0.46 at 24 months (P = 0.137). The number of injections (mean ± standard deviation) within the 2-year treatment course was 10.95 ± 3.65. At month 24 of the TnE regimen, the treatment interval was extended to ≥ 16 weeks in 60.5% of all cases and to 78.9% of the PCV cases. After three loading injections, persistent subretinal fluid and intraretinal fluid were predictive of more frequent injections (P = 0.026) and poorer visual outcomes (P = 0.050), respectively. Conclusion Aflibercept combined with a TnE regimen was effective in treating nAMD and PCV in a real-world setting. The treatment interval could be extended to ≥ 16 weeks in 60.5% of the cases after a 2-year treatment regimen. OCT can be used to predict the treatment course and visual outcomes. |
| first_indexed | 2024-03-08T14:19:22Z |
| format | Article |
| id | doaj.art-9ee629525ce845fdaba9c928383f99ed |
| institution | Directory Open Access Journal |
| issn | 2193-8245 2193-6528 |
| language | English |
| last_indexed | 2024-03-08T14:19:22Z |
| publishDate | 2023-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Ophthalmology and Therapy |
| spelling | doaj.art-9ee629525ce845fdaba9c928383f99ed2024-01-14T12:14:22ZengAdis, Springer HealthcareOphthalmology and Therapy2193-82452193-65282023-11-0113138539610.1007/s40123-023-00850-6Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal VasculopathyChu-Hsuan Huang0Tso-Ting Lai1Chang-Hao Yang2Yi-Ting Hsieh3Department of Ophthalmology, Cathay General HospitalDepartment of Ophthalmology, National Taiwan University HospitalDepartment of Ophthalmology, National Taiwan University HospitalDepartment of Ophthalmology, National Taiwan University HospitalAbstract Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical coherence tomography (OCT) to predict treatment outcomes. Methods Patients diagnosed with nAMD or PCV who received an intravitreal injection of aflibercept following the TnE regimen for ≥ 2 years were retrospectively reviewed. Data on best-corrected visual acuity (BCVA), number of injections, treatment interval, and OCT biomarkers, including central macular thickness, presence of subretinal fluid (SRF), and serous pigmented epithelial detachment, were collected at baseline and at 3, 6, 12, 18, and 24 months after the first injection. Results A total of 43 patients were enrolled in this study, 24 of whom were diagnosed with nAMD and 19 with PCV. The BCVA in logMAR (mean ± standard deviation) improved from 0.75 ± 0.41 (baseline) to 0.60 ± 0.41 (P = 0.002) at 3 months after treatment initiation, and further improved to 0.66 ± 0.46 at 24 months (P = 0.137). The number of injections (mean ± standard deviation) within the 2-year treatment course was 10.95 ± 3.65. At month 24 of the TnE regimen, the treatment interval was extended to ≥ 16 weeks in 60.5% of all cases and to 78.9% of the PCV cases. After three loading injections, persistent subretinal fluid and intraretinal fluid were predictive of more frequent injections (P = 0.026) and poorer visual outcomes (P = 0.050), respectively. Conclusion Aflibercept combined with a TnE regimen was effective in treating nAMD and PCV in a real-world setting. The treatment interval could be extended to ≥ 16 weeks in 60.5% of the cases after a 2-year treatment regimen. OCT can be used to predict the treatment course and visual outcomes.https://doi.org/10.1007/s40123-023-00850-6AfliberceptAge-related macular degenerationPolypoidal choroidal vasculopathyTreat-and-extend regimenVascular endothelial growth factor |
| spellingShingle | Chu-Hsuan Huang Tso-Ting Lai Chang-Hao Yang Yi-Ting Hsieh Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Ophthalmology and Therapy Aflibercept Age-related macular degeneration Polypoidal choroidal vasculopathy Treat-and-extend regimen Vascular endothelial growth factor |
| title | Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy |
| title_full | Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy |
| title_fullStr | Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy |
| title_full_unstemmed | Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy |
| title_short | Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy |
| title_sort | two year real world results for aflibercept using the treat and extend regimen in neovascular age related macular degeneration and polypoidal choroidal vasculopathy |
| topic | Aflibercept Age-related macular degeneration Polypoidal choroidal vasculopathy Treat-and-extend regimen Vascular endothelial growth factor |
| url | https://doi.org/10.1007/s40123-023-00850-6 |
| work_keys_str_mv | AT chuhsuanhuang twoyearrealworldresultsforafliberceptusingthetreatandextendregimeninneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT tsotinglai twoyearrealworldresultsforafliberceptusingthetreatandextendregimeninneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT changhaoyang twoyearrealworldresultsforafliberceptusingthetreatandextendregimeninneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT yitinghsieh twoyearrealworldresultsforafliberceptusingthetreatandextendregimeninneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy |